Marizyme Financials
This page shows Marizyme (MRZM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2023 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Marizyme's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Marizyme has an operating margin of -5278.1%, meaning the company retains $-5278 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -15985.5% the prior year.
Marizyme's revenue surged 176.6% year-over-year to $646K, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Marizyme carries a low D/E ratio of -4.29, meaning only $-4.29 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 77/100, indicating a strong balance sheet with room for future borrowing.
Marizyme's current ratio of 0.04 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Marizyme passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Marizyme generates $0.07 in operating cash flow (-$4.7M OCF vs -$69.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Marizyme generated $646K in revenue in fiscal year 2023. This represents an increase of 176.6% from the prior year.
Marizyme's EBITDA was -$33.2M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 8.9% from the prior year.
Marizyme reported -$69.5M in net income in fiscal year 2023. This represents a decrease of 82.2% from the prior year.
Marizyme earned $-1.53 per diluted share (EPS) in fiscal year 2023. This represents a decrease of 62.8% from the prior year.
Cash & Balance Sheet
Marizyme held $148K in cash against $0 in long-term debt as of fiscal year 2023.
Marizyme had 132M shares outstanding in fiscal year 2023. This represents an increase of 225.2% from the prior year.
Margins & Returns
Marizyme's gross margin was 70.9% in fiscal year 2023, indicating the percentage of revenue retained after direct costs. This is down 5.9 percentage points from the prior year.
Marizyme's operating margin was -5278.1% in fiscal year 2023, reflecting core business profitability. This is up 10707.4 percentage points from the prior year.
Marizyme's net profit margin was -10767.8% in fiscal year 2023, showing the share of revenue converted to profit. This is up 5578.4 percentage points from the prior year.
Capital Allocation
Marizyme invested $2.2M in research and development in fiscal year 2023. This represents a decrease of 45.3% from the prior year.
MRZM Income Statement
| Metric | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $33K-78.2% | $151K-17.1% | $182K-1.7% | $185K+43.2% | $129K | N/A |
| Cost of Revenue | N/A | N/A | $10K-80.0% | $48K-5.4% | $51K+2.8% | $50K+26.3% | $39K | N/A |
| Gross Profit | N/A | N/A | $23K-77.3% | $102K-21.6% | $131K-3.4% | $135K+50.6% | $90K | N/A |
| R&D Expenses | $344K+10.2% | $312K-3.0% | $322K-16.9% | $387K-21.4% | $492K-28.8% | $691K+14.1% | $606K | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -$1.4M+14.7% | -$1.6M-15.8% | -$1.4M+93.8% | -$22.3M-359.0% | -$4.9M-1.1% | -$4.8M-125.2% | -$2.1M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.0M+73.6% | -$7.4M-37.8% | -$5.4M-23.9% | -$4.4M+83.6% | -$26.5M+26.4% | -$36.1M-1312.5% | -$2.6M | N/A |
| EPS (Diluted) | $-0.01+83.3% | $-0.06-50.0% | $-0.04 | N/A | $-0.58+31.0% | $-0.84-1300.0% | $-0.06 | N/A |
MRZM Balance Sheet
| Metric | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $21.3M-1.3% | $21.5M-0.2% | $21.6M-2.0% | $22.0M-40.4% | $36.9M-0.2% | $37.0M-3.4% | $38.3M-1.1% | $38.7M |
| Current Assets | $855K-7.3% | $922K+25.5% | $735K-24.1% | $969K-26.3% | $1.3M+24.2% | $1.1M-43.7% | $1.9M-3.9% | $2.0M |
| Cash & Equivalents | $64K+1120.5% | $5K-15.0% | $6K-95.9% | $148K-68.7% | $475K+131.4% | $205K-37.8% | $330K-35.4% | $511K |
| Inventory | $27K0.0% | $27K+76.7% | $15K-38.8% | $25K-74.9% | $99K-29.1% | $140K-20.8% | $177K-18.1% | $216K |
| Accounts Receivable | $2K | N/A | N/A | $60K+39.5% | $43K-40.8% | $73K-6.6% | $78K-11.0% | $88K |
| Goodwill | $5.4M0.0% | $5.4M0.0% | $5.4M0.0% | $5.4M-24.7% | $7.2M0.0% | $7.2M0.0% | $7.2M0.0% | $7.2M |
| Total Liabilities | $36.8M+3.7% | $35.5M+10.2% | $32.2M+12.2% | $28.7M-56.7% | $66.3M+54.0% | $43.1M+86.9% | $23.0M+8.3% | $21.3M |
| Current Liabilities | $30.0M+6.6% | $28.1M+9.6% | $25.7M+13.3% | $22.6M-59.7% | $56.1M+64.2% | $34.2M+325.8% | $8.0M+174.7% | $2.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$15.5M-11.4% | -$14.0M-31.2% | -$10.6M-58.7% | -$6.7M+77.2% | -$29.4M-383.1% | -$6.1M-140.0% | $15.2M-12.6% | $17.4M |
| Retained Earnings | -$170.3M-1.2% | -$168.4M-4.6% | -$160.9M-3.5% | -$155.5M-2.9% | -$151.2M-21.3% | -$124.6M-40.8% | -$88.5M-3.0% | -$86.0M |
MRZM Cash Flow Statement
| Metric | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$983K-34.1% | -$733K+9.4% | -$809K+33.4% | -$1.2M-5.3% | -$1.2M+3.8% | -$1.2M-6.9% | -$1.1M+29.4% | -$1.6M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $1.0M+42.3% | $732K+9.8% | $667K-24.9% | $887K-37.6% | $1.4M+32.5% | $1.1M+14.3% | $939K+2.7% | $915K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MRZM Financial Ratios
| Metric | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | 70.6%+2.7pp | 68.0%-3.9pp | 71.9%-1.2pp | 73.2%+3.6pp | 69.5% | N/A |
| Operating Margin | N/A | N/A | -4176.2%+10629.9pp | -14806.1%-12130.5pp | -2675.6%-75.2pp | -2600.4%-946.7pp | -1653.7% | N/A |
| Net Margin | N/A | N/A | -16425.2%-13533.3pp | -2891.9%+11731.6pp | -14623.4%+4909.0pp | -19532.4%-17551.7pp | -1980.7% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -16.8% | N/A |
| Return on Assets | -9.2%+25.3pp | -34.5%-9.5pp | -25.0%-5.2pp | -19.8%+52.1pp | -71.9%+25.7pp | -97.6%-90.9pp | -6.7% | N/A |
| Current Ratio | 0.030.0 | 0.030.0 | 0.03-0.0 | 0.04+0.0 | 0.020.0 | 0.03-0.2 | 0.23-0.4 | 0.67 |
| Debt-to-Equity | -2.37+0.2 | -2.54+0.5 | -3.03+1.3 | -4.29-2.0 | -2.26+4.8 | -7.08-8.6 | 1.51+0.3 | 1.22 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.04), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Marizyme's annual revenue?
Marizyme (MRZM) reported $646K in total revenue for fiscal year 2023. This represents a 176.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Marizyme's revenue growing?
Marizyme (MRZM) revenue grew by 176.6% year-over-year, from $233K to $646K in fiscal year 2023.
Is Marizyme profitable?
No, Marizyme (MRZM) reported a net income of -$69.5M in fiscal year 2023, with a net profit margin of -10767.8%.
What is Marizyme's EBITDA?
Marizyme (MRZM) had EBITDA of -$33.2M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
What is Marizyme's gross margin?
Marizyme (MRZM) had a gross margin of 70.9% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.
What is Marizyme's operating margin?
Marizyme (MRZM) had an operating margin of -5278.1% in fiscal year 2023, reflecting the profitability of core business operations before interest and taxes.
What is Marizyme's net profit margin?
Marizyme (MRZM) had a net profit margin of -10767.8% in fiscal year 2023, representing the share of revenue converted into profit after all expenses.
What is Marizyme's operating cash flow?
Marizyme (MRZM) generated -$4.7M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Marizyme's total assets?
Marizyme (MRZM) had $22.0M in total assets as of fiscal year 2023, including both current and long-term assets.
How much does Marizyme spend on research and development?
Marizyme (MRZM) invested $2.2M in research and development during fiscal year 2023.
What is Marizyme's current ratio?
Marizyme (MRZM) had a current ratio of 0.04 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is Marizyme's debt-to-equity ratio?
Marizyme (MRZM) had a debt-to-equity ratio of -4.29 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Marizyme's return on assets (ROA)?
Marizyme (MRZM) had a return on assets of -315.9% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Marizyme's cash runway?
Based on fiscal year 2023 data, Marizyme (MRZM) had $148K in cash against an annual operating cash burn of $4.7M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Marizyme's debt-to-equity ratio negative or unusual?
Marizyme (MRZM) has negative shareholder equity of -$6.7M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Marizyme's Piotroski F-Score?
Marizyme (MRZM) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Marizyme's earnings high quality?
Marizyme (MRZM) has an earnings quality ratio of 0.07x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Marizyme?
Marizyme (MRZM) scores 30 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.